Articles tagged with Sars Cov 2
Researchers at EPFL have computationally designed novel protein binders that attach seamlessly to key targets, including the SARS-CoV-2 spike protein, using deep learning-generated 'fingerprints' to characterize millions of protein fragments. This method demonstrates therapeutic potential for rapidly designing protein-based therapeutics.
The study found that COVID-19 vaccine-induced immunity rapidly declines after primary vaccination and booster doses, leading to a decrease in protection against Omicron and Delta infections. The results highlight the need for targeted vaccination strategies to combat the evolving SARS-CoV-2 virus.
Researchers successfully delivered stabilized divalent siRNA molecules to animal models that blocked SARS-CoV-2 and prevented infection. The technology is adaptable for other pulmonary diseases such as pulmonary fibrosis and respiratory viruses.
A study found that psychological factors, such as beliefs and attitude towards the COVID-19 vaccine, significantly contribute to the onset and severity of adverse effects. The researchers investigated how fear, trust, and expectations affect side effects and explained 30% of the intensity of symptoms.
Researchers have identified mechanisms behind the emergence of new and contagious coronavirus variants by analyzing over three million genome sequences. The study found that concordant substitutions occurring at other sites influence the likelihood of a substitution occurring at a specific site, leading to unexpected variant emergence.
A molecular autopsy revealed that a young child with mild COVID-19 symptoms died from cardiac arrest due to an atypical coronary artery anomaly and underlying Noonan syndrome, a rare genetic disorder.
Researchers found that non-mandatory measures had a greater impact on reducing travel distances and times, while mandatory measures only slightly affected these metrics. In contrast, strict metre rules and reopening of gyms increased distance travelled.
A systematic review and meta-analysis found that SARS-CoV-2 infection significantly increases the risk of Bell palsy, whereas vaccination poses a lower risk. The Pfizer/BioNTech vaccine did not differ significantly from the Oxford/AstraZeneca vaccine in terms of BP incidence.
Scientists have created a system that directly targets and degrades the SARS-CoV-2 viral RNA genome, reducing infection in mice. This method could be adapted to fight off many viruses and treat various diseases.
A world-leading international trial has found that the BCG vaccine does not protect healthcare workers against COVID-19, despite boosting 'front-line' immunity in infants and protecting against respiratory infections. The research involved 3988 healthcare workers and showed a higher risk of symptomatic COVID-19 in the BCG group.
Researchers discovered a 'cocktail' of human antibodies that show promise in fighting severe SARS-CoV-2 infections, including Omicron variants. The study revealed how the original Moderna vaccine could prompt the body to produce these broad-spectrum antibodies.
New research found that temperature and original viral concentration affect the persistence of Omicron variants on shipping materials. The study reveals that lower temperatures and higher viral concentrations increase stability, while room temperature poses a risk. Safety protocols for shipping goods can be improved with this knowledge.
A research team created the first human respiratory organoid culture system, enabling scientists to study COVID-19 and its variants. The study found that the BA.5 Omicron variant exhibits dramatically increased infectivity and replicative capacity in human nasal and airway organoids.
A treatment combining two antibodies against SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death. The treatment was effective against the delta variant and appeared safe, with significantly lower reports of side effects compared to a placebo.
Researchers successfully isolated infectious SARS-CoV-2 particles from hospital air samples collected over a year ago, demonstrating the presence of viable virus particles in aerosols. This breakthrough provides new insights into airborne transmission and informs the development of preventive strategies.
Researchers from Lund University have designed a cocktail of modified antibodies that tag the virus to be eliminated by the immune system. The study found that combining different combinations of these antibodies can improve their function, suggesting a potent clinical effect against SARS-CoV-2 and its variants.
A new study found that children with COVID-19 and pre-existing high-risk conditions can be effectively treated at home, avoiding hospitalization. The Hospital-in-the-Home program recorded a 21% increase in patients and a 132% jump in telehealth appointments.
A large study of over 600,000 individuals found a strong association between COVID-19 infection and the development of incident diabetes. The researchers estimate that SARS-CoV-2 infection may contribute to a 3% to 5% excess burden of diabetes at a population level.
Experts recommend managing SARS-CoV-2 like other endemic respiratory viruses using Standard and Transmission-based Precautions. They also suggest reconsidering pandemic-era strategies such as asymptomatic testing and contact tracing in the endemic era.
Researchers recognize the need for improved COVID-19 vaccines to prevent transmission and infection. Mucosal vaccines targeting the respiratory tract could be effective in blocking SARS-CoV-2 transmission and reducing disease burden.
Researchers identified potential novel receptors for SARS-CoV-2 that utilize multiple receptors to facilitate its life cycle. The study reveals a strong correlation between tissue age-dependency and SARS-CoV-2 infection-induced receptor expression, with older adults being more susceptible to severe outcomes.
A study published in JCI Insight found that pregnant women display robust immune responses to SARS-CoV-2 infection, comparable to those of non-pregnant women. Key differences were observed in the dynamics of innate immune cells at the first line of defense towards viral infections.
A new study found that SARS-CoV-2 presence on people's hands and frequently touched household surfaces significantly contributes to the spread of COVID-19. The research suggests that frequent handwashing, regular surface disinfection, and physical distancing can curb the virus's transmission.
Researchers identified potential neurological biomarkers of long COVID-19 in nonhuman primates, which could aid in diagnosis, monitoring, and treatment. The study found elevated proteins associated with neurodegenerative disorders in the brain, cerebrospinal fluid, and blood after SARS-CoV-2 infection.
A study published in the Journal of Internal Medicine found that patients with liver disease who took the drug ursodeoxycholic acid had a 46% lower odds of being infected with SARS-CoV-2. This was associated with reduced symptoms and severity of COVID-19.
Researchers found that COVID-19 infection leads to rapidly progressive dementia, blurring the lines between different types of dementia. Cortical atrophy and inflammation were key indicators, suggesting previously compromised brains have limited defense against new insults.
A recent Brazilian study found that the Spike protein from SARS-CoV-2 is implicated in post-COVID-19 memory loss, with researchers identifying TLR4 receptor as a potential therapeutic target. The study involved experiments with mice and showed that infusion of the Spike protein induced delayed memory impairment.
New research reveals SARS-CoV-2 spike protein mutations made the virus more rigid and improved its ability to transmit through nasal droplets and infect host cells. This could mean newer vaccines are effective for longer against emerging variants.
A WPI-led team used computational modeling to create a detailed picture of the SARS-COV-2 virus envelope, revealing its elliptical shape and changing structure. This discovery could lead to more effective therapies and vaccines, as well as a better understanding of the virus's properties.
A study published in Science Advances reveals that viral SARS-CoV-2 variants are developing resistance to protease inhibitors, including Paxlovid. Researchers warn that this could undermine the effectiveness of antiviral treatments and highlight the need for next-generation compounds with different resistance profiles.
Researchers found that SARS-CoV-2 infection causes drastic changes to RNA modifications, including the loss of m6A modification. This disruption may lead to persistent COVID-like symptoms and provide a new potential drug target against COVID-19. The study's results could also shed light on chronic post-COVID conditions.
A team of scientists has designed a molecule that targets the PLpro enzyme in SARS-CoV-2, limiting its replication and hampering the host's immune response. The covalent inhibitor shows promise as a new treatment for COVID-19 and other viral diseases.
Researchers found that COVID-19 vaccination generates robust T cell responses in haematology patients, on par with healthy individuals. The study provides key insights for future immunisation strategies and shows that mRNA vaccines can elicit strong T cell immunity in patients with co-morbidities.
A small molecule discovered by University of Houston researchers could potentially shorten the course of SARS-CoV-2 infection, offering a new alternative treatment option for COVID-19. The compound, CD04872SC, has shown promise in neutralizing the virus and its variants Delta and Omicron.
Researchers examine how chronological and biological age impact vaccine effectiveness, finding that both factors influence immune system capacity to mount responses. The study highlights the need for further research into 'immune aging' risk and departures from healthy aging.
Researchers at the University of Helsinki have developed a nasal spray that is effective in preventing coronavirus infection, including the latest variants. The molecule, TriSb92, identifies a region in the spike protein common to all current variants and inhibits its functioning.
A cohort study found that nirmatrelvir treatment within five days of a positive COVID-19 test result was associated with reduced post-COVID-19 condition risk, regardless of vaccination status and prior infection history. The study suggests that nirmatrelvir may reduce the risk of long COVID across the risk spectrum.
Recent studies have found improved efficacy against SARS-CoV-2 infection with the third dose of the vaccine, leading to a reduction in hospitalization. Booster vaccinations also resulted in further increases in antibody responses, demonstrating strong and persistent immunity.
A new study by UC San Diego researchers found that COVID-19 subvariants like BA.4 and BA.5 evaded the body's natural defense, leading to rapid spread. Early treatment with Paxlovid may have left patients more susceptible to re-infection due to a weakened immune response.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
Researchers have identified a highly conserved region of the SARS-CoV-2 spike protein that could be targeted to boost human antibody responses against any coronavirus. The discovery could aid the development of more powerful antibody drugs and vaccines against COVID-19 and emerging coronaviruses.
A study published in Nature Immunology found that antibodies from previously infected patients can neutralize variants of the COVID-19 disease, including the Omicron variant. These broadly neutralizing antibodies have unique biochemical and structural features that enable them to block the virus from entering human cells.
A study by Indian Institute of Science researchers found that enhanced recombination in the SARS-CoV-2 Omicron variant resulted in new mutations affecting viral proteins, particularly those involved in host-cell binding. These mutations enabled the virus to evade immune defenses and infect host cells more efficiently.
A study published in Lancet Diabetes & Endocrinology found that the incidence of type 1 diabetes among Finnish children increased by 16% during the pandemic. Researchers believe that social isolation and lockdowns rather than SARS-CoV-2 infection may have contributed to this increase.
A research team from MedUni Vienna found that only neutralizing antibodies can inform us about protection against new infections. The study discovered a previously unknown weak point of the virus, which is a conserved site on the surface of the virus.
A study published in Gut journal found that COVID-19 patients experienced gastrointestinal symptoms more frequently than non-infected patients. The research also discovered a higher incidence of irritable bowel syndrome among infected individuals, with symptoms lasting up to 12 months after hospitalization.
A new study has found that SARS-CoV-2 infection damages the CD8+ T cell response, which is crucial for fighting the virus. Vaccination after infection can still provide protection, but booster shots may be needed to boost immune-cell responses.
Research suggests that an underactive immune response may explain the link between obesity and severe COVID-19. Obese patients with COVID-19 have been found to have blunted inflammatory responses, producing suboptimal levels of molecules needed to fight the infection.
A recent study found that while social factors were hypothesized to influence UFO reports, no association was found with the COVID-19 pandemic's stress and anxiety measures. An alternative explanation was proposed: regular Starlink satellite launches may have led to increased sightings.
A new study describes an optimized method for isolating and identifying nanobodies targeting SARS-CoV-2, which could lead to the development of effective therapies. The approach uses a yeast display method, reducing costs and time required for screening nanobody libraries.
Researchers at Karolinska Institutet discovered that children's memory T cells react to SARS-CoV-2, providing immunity against COVID-19. The study found strong cross-reactivity between coronaviruses causing common colds and SARS-CoV-2.
A study of 1,440 Canadian children with SARS-CoV-2 infection found that presenting symptoms have changed over time, but severe outcomes among children have remained relatively consistent. The research suggests that while the virus's characteristics are evolving, its impact on young patients remains a concern.
A new study found that New York City rats are susceptible to Alpha, Delta, and Omicron variants of SARS-CoV-2. The researchers also demonstrated a possible link between the virus and rat populations in the city's sewer systems.
Researchers found that COVID-19 survivors with persistent symptoms were more likely to be sedentary, especially those experiencing breathlessness and fatigue. The study, supported by FAPESP, included 614 participants who were analyzed for physical activity and lifestyle habits.
A new study published at the European Congress of Clinical Microbiology & Infectious Diseases found that healthcare workers infected with the original SARS-CoV-2 virus were more likely to experience long Covid symptoms than those who had the omicron variant. The research suggests that omicron may be less likely to lead to long Covid, p...
A new study analyzing household transmission data found that the top 20% of infected individuals cause three times more infections than the average person, highlighting individual differences in infectiousness.
A University of Michigan study suggests that exhaled breath contains unique volatile organic compounds (VOCs) that can mark distinction between COVID-19, variants and non-COVID illnesses. The researchers developed a portable gas chromatography device to analyze breath samples with high accuracy.
A global team of researchers created an algorithmic tool to identify existing drugs that could be effective against the next pandemic. The PHENotype SIMulator (PHENSIM) uses computer experiments to analyze biomolecules and predict antiviral effects, identifying potential candidates for repurposing.
A new UNCG study confirms that SARS-CoV-2 destroys the antioxidant activity of key human selenoproteins, weakening immunity and enabling virus replication. The findings suggest investigating selenium supplementation and dietary sulfur compounds as potential symptomatic treatments for COVID patients.
A Scripps Research and eMed study found that COVID-19 rebound cases are more common than previously reported, affecting up to 14.2% of Paxlovid-treated patients and 9.3% of untreated patients. Rebound is measured by positive test results or symptom recurrence after initial clearance.